A Look At Merck’s Late Stage Pharmaceuticals Pipeline
- Tuesday, December 11, 2018, 15:09
- Market
- Add a comment
Merck (NYSE:MRK) has a strong late stage pharmaceuticals pipeline, and it could be worth as much as $13 billion, or over 6% of its current market value, according to our estimates. Several drugs in the pipeline are capable of generating more than $1 billion in peak sales. Merck’s drug pipeline…
https://www.forbes.com/sites/greatspeculations/2018/12/11/a-look-at-mercks-late-stage-pharmaceuticals-pipeline/
About the Author
admin123 has written 23404 stories on this site.
